
    
      A phase-II, double-blind, placebo-controlled, randomised, parallel-group,multi-centre study
      to assess the efficacy and safety of two staggered dose levels of inhaled once daily AZD5423
      or twice daily budesonide for 12 weeks in COPD patients on a background therapy of
      formoterol.
    
  